AnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results
Robust Half-Life and Extended Pharmacodynamic Activity Following a Single Dose of ANB019 Supports Advancement of ANB019 into Phase 2 Trials for IL-36-Associated Orphan Inflammatory Diseases SAN DIEGO, Nov. 06, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. ( …